Imaging of the Choroid Plexus with Prior Administration of Sn(11)-pyrophosphate

A. Komatani*, K. Yamaguchi*, K. Uemura**
*Department of Radiology, Yamagata University, School of Medicine, Yamagata
**Department of Radiology, Research Institute of Brain and Blood Vessels, Akita

A clear image of the choroid plexus was obtained unexpectedly in a brain scintigraphy by $^{99m}$Tc-pertechnetate, 24 hours before which a bone scintigraphy had been performed using $^{99m}$Tc-pyrophosphate. If RI-imaging of the ventricular system become possible, its information must be very useful for the diagnosis of the brain. This situation led us to investigate the intentional imaging of the choroid plexus by prior administrations of Sn(11)-pyrophosphate.

(Method) Prior administration of Sn(11)-pyrophosphate used in radiopharmaceutical preparations was made. Three to fortyeight hours later, $^{99m}$Tc-pertechnetate was injected and from this time the sequential image of the brain was stored into a data recorder system with a gamma camera. Thereafter, time course of the RI accumulation in the choroid plexus was analyzed.

(Result and discussion) The peak of count rate in the choroid plexus was noted between the range from 60 to 90 min after $^{99m}$Tc-pertechnetate injection. The count rate ratio of the choroid plexus to the outside region increased gradually and reached plateau about 120 to 180 min after the injection. In such a time range we can get the clearest image of the choroid plexus.

The mechanism of the selective concentration of $^{99m}$Tc-pertechnetate to the choroid plexus with prior administration of Sn(11)-pyrophosphate is still obscured. But, we may consider that the tin in the pyrophosphate accumulate at first ito the choroid plexus and then the tin collects the $^{99m}$Tc-pertechnetate by reducing process.

Clear image of the choroid plexus is very effective to detect the displacement of the ventricular system of the brain. Especially, it is useful for the diagnosis of some space-occupying lesions which are not visualized by ordinary scintigraphy only with $^{99m}$Tc-pertechnetate administration. Actual clinical cases were also presented to show the advantage of our method.

Clinical Evaluation of Radioimmunoassay for Astroprotein in Cerebrospinal Fluid

Akira Matsumoto*, Tatsuuro Akioka*, Shuzo Okumura*, Shojiro Okao**
and Kousuke Ohta**
*Neurosurgical Service, National Hospital in Okayama
**Neurosurgical Service, Fukuyama Ohta Hospital

Mori et al. (1970) revealed an astrocyte-specific cerebroprotein and designated it as astroprotein. They also established the radioimmunoassay method for measuring astroprotein in cerebrospinal fluid and reported that this technique might be applicable as a screening test for glioma. At the same time there is a possibility astroprotein in cerebrospinal fluid may be increase following cerebral tissue damage, because it exists in a fibrillary astrocyte of normal brain. The purpose of the present study is to detect astroprotein in cerebrospinal fluid by radioimmunoassay, attempting to clarify the diagnostic value of astroprotein for cerebral tissue damage. A hundred patients with head injuries as well as other non-tumor diseases has been examined and the following results were obtained:

1) Astroprotein in cerebrospinal fluid from patients of control group without organic cerebral tissue damages, such as cervical spondylosis, Menière's disease, neurosis and so on, was found generally under 30 ng/ml.

2) Astroprotein in cerebrospinal fluid from patients with cerebral concussions was also found